Teva

Name

Teva

Legal name

Teva Italia S.r.l.

Website

https://tevaitalia.it

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Generic pharmaceuticals
• Specialty medicines
• Biosimilars development
• Long-acting injectables
• CNS therapeutics

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic pharmaceuticals: Teva is the world's largest generic drug manufacturer with a portfolio of over 3,600 products globally, generating revenue through the sale of off-patent pharmaceuticals across nearly all therapeutic areas. Generic drugs cost less than originator drugs due to avoided R&D costs of the original molecule. Teva is the #1 pharmaceutical company in Italy for generic drug sales in both retail pharmacies and hospitals. In 2020, Teva invested nearly $1 billion in R&D activities with over 1,160 generic drugs in its pipeline.
2. Specialty/innovative medicines: Teva develops and commercializes specialty branded medicines in CNS (Austedo, Ajovy, Copaxone), respiratory, oncology, and immunology. Revenue comes from prescription drug sales to healthcare systems, pharmacies, and hospitals. Austedo (Huntington's disease therapy) surged 41% in Q1 2026. Teva's innovative medicines pipeline includes duvakitug (IBD, partnered with Sanofi), ecopipam (Tourette syndrome, via Emalex acquisition), olanzapine LAI (schizophrenia), and TEV-53408 antibody (celiac disease/vitiligo).
3. Biosimilars: Teva develops and commercializes biosimilar products — biologic drugs comparable to reference products after patent expiry — in partnership with Alvotech (Simponi, Eylea) and through own development (Denosumab biosimilar Ponlimsi, Omalizumab biosimilar). FDA approved Teva's Denosumab biosimilar Ponlimsi (denosumab-adet) in April 2026. FDA and EMA accepted filing applications for Omalizumab biosimilar.
4. Royalty and milestone income: Teva generates recurring royalty income from products developed by partners using licensed technology. Most notably, Teva's net sales of UZEDY reached $215 million (up 52.5% year-over-year), with MedinCell receiving 42% royalty growth to EUR 9.3 million. Teva also receives royalties from Blackstone on duvakitug if approved and commercialized.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Teva manufactures and markets generic pharmaceutical products across nearly all therapeutic areas and develops, manufactures, and commercializes specialty/innovative medicines focused on CNS, respiratory, immunology, and oncology conditions. The company also invests in a biosimilars pipeline and in novel long-acting injectable and antibody therapeutics, supported by vertically integrated API and finished-dose manufacturing operations across approximately 60 markets.

Product overview

Teva is a global pharmaceutical company operating across three main business segments: generic medications (farmaci equivalenti), specialty/innovative medicines, and biosimilars. The generic portfolio comprises over 3,600 products spanning virtually all therapeutic areas including gastrointestinal, cardiovascular, dermatological, anti-infectives, nervous system, respiratory, and sensory organs. Specialty products include Ajovy (fremanezumab) for migraine prevention, Austedo (deutetrabenazine) for Huntington's disease and tardive dyskinesia, UZEDY (risperidone long-acting injectable) for schizophrenia, and the pipeline includes TEV'749 long-acting olanzapine, duvakitug (IBD therapy with Sanofi partnership), and ecopipam (Tourette syndrome from Emalex acquisition). Biosimilar products include AVT05 (Simponi), AVT06 (Eylea), Omalizumab, and Ponlimsi (denosumab). Teva also operates digital platforms including TevaLab for healthcare professionals, Synapses Point for neurologists, and the Home Ground Schizophrenia Community for patients. The company generates revenue from patient support programs like the Humanizing Health Awards and T-TOP osteoporosis program.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Portfolio Teva's broad generics catalog spans small-molecule oral, injectable, and specialty generic medicines sold to wholesalers, hospital systems, pharmacies, and national health services worldwide for cost-sensitive substitution of off-patent branded therapies.
• Ajovy (fremanezumab) Anti-CGRP monoclonal antibody approved for the preventive treatment of migraine in adults; commercialized by Teva's specialty/innovative medicines franchise and dispensed predominantly through specialty pharmacy channels.
• Austedo (deutetrabenazine) Branded VMAT2 inhibitor indicated for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults; distributed through Teva's specialty neurology sales force and specialty pharmacy networks.
• Copaxone (glatiramer acetate) Long-established Teva specialty medicine for relapsing multiple sclerosis; injectable immunomodulator sold globally through specialty pharmacy and hospital channels and a longstanding generator of royalty and product income.
• UZEDY (risperidone long-acting injectable) Long-acting injectable formulation of risperidone indicated for the treatment of schizophrenia in adults; commercialized through Teva's specialty psychiatry franchise in the U.S.
• TEV'749 (long-acting olanzapine) Investigational long-acting injectable olanzapine product being developed by Teva for the treatment of schizophrenia; positioned as a follow-on to UZEDY in the company's long-acting injectable psychiatry franchise.
• Duvakitug Anti-IL-15 monoclonal antibody under development by Teva for inflammatory diseases of the gut and other immune-mediated conditions.
• Ecopipam First-in-class dopamine D1 receptor antagonist that Teva acquired and is developing for the treatment of Tourette syndrome and other CNS indications.
• AVT05 (proposed golimumab / Simponi biosimilar) Biosimilar candidate referencing golimumab (Simponi), part of Teva's emerging immunology biosimilars pipeline.
• AVT06 (proposed aflibercept / Eylea biosimilar) Biosimilar candidate referencing aflibercept (Eylea) being developed by Teva for retinal disease indications.
• Ponlimsi (denosumab biosimilar) Biosimilar candidate referencing denosumab (Prolia/Xgeva) being developed by Teva for osteoporosis and bone-metastasis indications.
• Omalizumab biosimilar Biosimilar candidate referencing omalizumab (Xolair) being developed by Teva for allergic asthma and chronic spontaneous urticaria.
• TEV-53408 (anti-TL1A antibody) Anti-TL1A monoclonal antibody in Teva's early-stage pipeline being investigated for inflammatory bowel disease and other immune-mediated conditions.
• Macitentan generic Generic version of macitentan for the treatment of pulmonary arterial hypertension (PAH); part of Teva's specialty generics portfolio.

Quantifiable outcome

• Over 100 million packages of Teva products sold per year in Italy (approx. 200 packages per minute)
• +6 more outcomes

Named customers6 records

Segments8 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered major, minor and core.

• AlvotechmajorStrategic or Co-development Partner · 15 June 2026Alvotech handles development and manufacturing of biosimilars while Teva manages commercialization under a partnership. Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi/Simponi Aria biosimilar, referencing J&J) and AVT06 (Eylea biosimilar, referencing Regeneron) in June 2026. The FDA review is expected within six months. Alvotech also has AVT03 (Prolia/Xgeva biosimilar) and AVT04 (Stelara biosimilar) in its pipeline with Teva commercialization rights.
• Ukko LaboratoriesminorStrategic or Co-development Partner · 14 June 2026Ukko Laboratories, founded by Prof. Yanay Ofran, has cooperation agreements with pharmaceutical giants including Teva, Merck, and Nektar Therapeutics. Ukko is developing Ukko18, the world's first RNA-based therapy for peanut allergies in Phase 1 trials in Australia/New Zealand. Both Ukko and Ofran's other company Biolojic Design/Aulos Bioscience have raised over $200 million combined and have cooperation agreements with Teva.
• Emalex BiosciencescoreStrategic or Co-development Partner · 30 April 2026Teva acquired Emalex Biosciences for up to $900 million ($700 million upfront), marking the company's first M&A in nearly a decade since the $40.5 billion Actavis merger in 2016. The deal centers on ecopipam, a selective dopamine D1 receptor antagonist for Tourette's syndrome that has completed Phase 3 trials with potential FDA approval by 2027 and $1 billion peak sales according to Jefferies analysts. Ecopipam has orphan drug designation for pediatric use.
• Rezon BiominorChannel Partner/ Reseller/ Distributor · 15 March 2026Rezon Bio, a Polish biotech company spun off from Polpharma Biologics and backed by Jerzy Starak, is positioning itself as a contract drug manufacturer to capture orders currently fulfilled in Chinese factories. The company has secured FDA accreditation as the only Polish firm authorized to manufacture biologic drugs for the U.S. market. Rezon Bio has existing partnerships with Sandoz and Teva, aiming to leverage EU reshoring policies for Western pharmaceutical supply chain diversification.
• ClarivateminorStrategic or Co-development Partner · 1 January 2026Clarivate partnered with Teva to support antimicrobial stewardship programs in Germany and Kenya, improving responsible antibiotic use through data-driven interventions. The partnership is part of Clarivate's 2025 Sustainability Report initiatives. Teva is one of several partners in Clarivate's antimicrobial stewardship efforts.
• MedinCellcoreStrategic or Co-development Partner · 1 April 2023MedinCell developed UZEDY (risperidone long-acting injectable) using its proprietary BEPO technology. Teva commercializes UZEDY in the United States. In FY2025-26, MedinCell received 42% royalty growth to EUR 9.3 million from UZEDY, while Teva reported $215 million in UZEDY net sales (up 52.5% year-over-year, with 2026 outlook of $250-280M). Royalty income now represents 38% of MedinCell's total revenue versus 22% previously. Teva also accepted MedinCell's olanzapine LAI NDA for Q4 2026 US launch. MedinCell has 15 active programs across neuroscience, immunology, oncology, endocrinology, and infectious diseases.
• SanoficoreStrategic or Co-development Partner · 1 January 2023Teva and Sanofi co-develop and co-commercialize duvakitug (TEV'574), an investigational TL1A-blocking monoclonal antibody for inflammatory bowel disease (ulcerative colitis and Crohn's disease). Sanofi paid Teva $500 million upfront in 2023 plus up to $1 billion in milestones. Both companies plan to co-commercialize globally. Duvakitug demonstrated durable Phase IIb efficacy with 58% UC and 55% CD patients maintaining remission at 44 weeks. Phase III trials (STARSCAPE for CD, SUNSCAPE for UC) are underway. Peak sales potential estimated at $2-5 billion.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sandoz: Sandoz, spun off from Novartis in 2023, is the world's #1 generics manufacturer by some measures and Teva's closest direct competitor across small-molecule generics and biosimilars. Overlapping in retail, hospital, and biosimilar channels globally, Sandoz directly contests Teva's Italian leadership, US generics share, and biosimilar launches (Hyrimoz, Erelzi).
• Viatris: Viatris (formed by Mylan + Upjohn, Pfizer's off-patent unit) competes directly with Teva across branded generics, complex generics, and biosimilars globally. Teva and Viatris/Mylan have a long history of Paragraph IV challenges, antitrust disputes (Copaxone), and direct contesting of US, European, and emerging market retail/hospital contracts.
• Lupin Pharmaceuticals: Lupin is a top-3 Indian generic manufacturer with strong US and emerging-market presence competing head-to-head with Teva on complex generics, ANDAs, and biosimilars. Both companies target the same cardiovascular, CNS, and respiratory generics opportunities and increasingly complex specialty generics and biosimilars.
• Aurobindo Pharma: Aurobindo is one of the largest Indian generic manufacturers, with US and EU operations directly overlapping Teva's small-molecule generic portfolio, especially in oral solids, injectables, and ARVs. Both target the same US retail/hospital channel with similar cost-led strategies.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian-headquartered generics and biosimilars manufacturer with strong US and Russian presence competing directly with Teva in retail and hospital generics, complex injectables, and biosimilars. Comparable in product breadth and geographic spread to Teva's International Markets segment.
• Hikma Pharmaceuticals: Hikma is a Jordan-headquartered generics and injectables specialist competing directly with Teva in US hospital injectables, oral generics, and branded specialty. Both companies have meaningful MENA and US hospital footprints and overlap in oncology, anti-infective, and respiratory generics.
• Apotex: Apotex is one of Canada's largest generic manufacturers with substantial US presence, directly competing with Teva across retail generics, with particular strength in Canadian, US, and Latin American markets that overlaps with Teva's generic portfolio.
• Amneal Pharmaceuticals: Amneal is a major US-focused specialty generics, injectables, and biosimilars company competing directly with Teva across complex generics (e.g., Apotex/Teva inhaler litigation, generic Korlym) and biosimilars, with similar pricing dynamics in the US generics market.

Broad incumbents

• Sanofi: Sanofi is Teva's partner on duvakitug (TL1A for IBD) and a broad incumbent across specialty, vaccines, and consumer health. Comparable as a specialty/innovative pharmaceutical major with CNS and immunology presence that overlaps Teva's specialty franchise and provides the strategic partnership counterpoint.

Emerging players

• Alvotech: Alvotech is a pure-play biosimilar developer commercializing AVT05 (Simponi biosimilar), AVT06 (Eylea biosimilar), and other biosimilars through its Teva partnership. Emerging player in biosimilars with direct overlap in Teva's biosimilar strategy and a meaningful commercial dependency relationship with Teva.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/tevaitalia
• LinkedInlinkedin.com/company/teva-pharmaceuticals
• Instagraminstagram.com/teva_it
• Xx.com/teva_it

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva